Advertisement
Research Article

Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma

  • Birgit Engesæter mail,

    birgite@rr-research.no

    Affiliation: Department of Tumor Biology, Oslo University Hospital, Oslo, Norway

    X
  • Olav Engebraaten,

    Affiliations: Department of Tumor Biology, Oslo University Hospital, Oslo, Norway, Department of Oncology, Oslo University Hospital, Oslo, Norway, Institute for Clinical Research, Medical Faculty, University of Oslo, Oslo, Norway

    X
  • Vivi Ann Flørenes,

    Affiliation: Department of Pathology, Oslo University Hospital, Oslo, Norway

    X
  • Gunhild Mari Mælandsmo

    Affiliations: Department of Tumor Biology, Oslo University Hospital, Oslo, Norway, Department of Pharmacy, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway

    X
  • Published: September 20, 2012
  • DOI: 10.1371/journal.pone.0045492

About the Authors

Birgit Engesæter, Olav Engebraaten, Gunhild Mari Mælandsmo
Department of Tumor Biology, Oslo University Hospital, Oslo, Norway
Olav Engebraaten
Department of Oncology, Oslo University Hospital, Oslo, Norway
Olav Engebraaten
Institute for Clinical Research, Medical Faculty, University of Oslo, Oslo, Norway
Vivi Ann Flørenes
Department of Pathology, Oslo University Hospital, Oslo, Norway
Gunhild Mari Mælandsmo
Department of Pharmacy, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway

Corresponding Author

Email: birgite@rr-research.no

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: BE OE VF GMM. Performed the experiments: BE VF. Analyzed the data: BE OE VF GMM. Contributed reagents/materials/analysis tools: BE OE GMM. Wrote the paper: BE. Discuission of the manuscript and approcal of the final version: BE OE VF GMM.